close
References
  1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail. 2022. [Epub ahead of print].
  2. O'Connor KD, Brophy T, Fonarow GC, et al. Testing for coronary artery disease in older patients with new-onset heart failure: findings from Get With The Guidelines-Heart Failure. Circ Heart Fail. 2020;13(4):e006963.
  3. Velazquez EJ, Morrow DA, DeVore AD, et al; PIONEER-HF Investigators. Angiotensin–neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539-548.
  4. Morrow DA, Velazquez EJ, DeVore AD, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Circulation. 2019;139(19):2285-2288.
  5. Sacubitril/Valsartan. Prescribing information. Novartis Pharmaceuticals Corporation; 2021.
  6. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883-1893.
  7. Vericiguat. Prescribing information. Merck & Co., Inc.; 2021.
  8. Bonow RO, O'Gara PT, Adams DH, et al. 2020 focused update of the 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee [published correction appears in J Am Coll Cardiol. 2020;75(23):3000]. J Am Coll Cardiol. 2020;75(17):2236-2270.
  9. Writing Committee, Maddox TM, Januzzi JL Jr, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772-810.
  10. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study [published correction appears in Lancet. 2010;376(9757):1988. Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabadán, I Roldan]; Leva, M [corrected to Ieva, M]]. Lancet. 2010;376(9744):875-885.
  11. Greene SJ, Velazquez EJ, Anstrom KJ, et al. Pragmatic design of randomized clinical trials for heart failure: rationale and design of the TRANSFORM-HF trial. JACC Heart Fail. 2021;9(5):325-335.
  12. McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008.
  13. Dapagliflozin. Prescribing information. AstraZeneca; 2021.
  14. Vaidya Y, Riaz S, Dhamoon AS. Left Ventricular Assist Devices. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 22, 2022.
  15. Epstein AE, DiMarco JP, Ellenbogen KA, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Heart Rhythm Society. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013;61(3):e6-75.
  16. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2018;138:e272-e391.
  17. European Society of Cardiology. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Accessed March 9, 2022. www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-and-Chronic-Heart-Failure